



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|---|-------------|----------------------|-----------------------------|------------------|
| 10/820,677 | 04/08/2004 | Lisa Lynn Shafer | P-10966.00 US | 8518 |
| 27581 | 7590 | 08/13/2007 | | |
| MEDTRONIC, INC. 710 MEDTRONIC PARKWAY NE MINNEAPOLIS, MN 55432-9924 | | | EXAMINER GEDEON, BRIAN T | |
| | | | ART UNIT | PAPER NUMBER |
| | | | 3766 | |
| | | | MAIL DATE | DELIVERY MODE |
| | | | 08/13/2007 | PAPER |

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|------------------------------|--------------------------------------|--|--|
| Office Action Summary | Application No. 10/820,677 | Applicant(s) SHAHER, LISA LYNN | |
| | Examiner Brian T. Gedeon | Art Unit 3766 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 22 May 2007.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4, 8-10, 15, 17-42, 54-67 and 130-199 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4, 8-10, 15, 17-42, 54-67, and 130-199 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>5/1/2007</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

1. Acknowledgement is made of Applicant's Amendment, which was received by the Office on 22 May 2007. Claims 68-70 have been cancelled. Claims 1-4, 8-10, 15, 17-42, 54-67, and 130-199 are pending.
2. The declaration filed on 22 May 2007 under 37 CFR 1.131 is sufficient to overcome the Kees et al. reference.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

4. **Claims 1-5, 8-10, 15, 17, 54-65, and 139-199 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Rezai (US 2002/0116030).**

In regard to claims 1-5, 17, 54-56, and 139-199, Rezai discloses a method comprising stimulating a sympathetic neuron of a mammalian subject in an amount effective to inhibit the release of a proinflammatory mediator (see Rezai Abstract, page 1, paragraphs 4-7 and page 2, paragraphs 14 and 19). The Examiner takes the position that the oscillating electrical signal comprising a plurality of electrical pulses of the Rezai method, operated at a frequency range between about 2 Hz and 2500 Hz, having a

Art Unit: 3766

voltage between about 0.1 V to about 20 V and a pulse width between 10 microseconds to about 1,000 microseconds is synonymous with an "amount effective to inhibit the release of a proinflammatory mediator" due to Applicant's disclosure pages 17 and 26-28 (see Rezai page 2, paragraph 19 and page 5, paragraph 38). The Examiner also notes that although the method of Rezai is not explicitly disclosed "to inhibit the release of a "proinflammatory mediator", the oscillating electrical signal comprising a plurality of electrical pulses of the Rezai method is capable of inhibiting the release of a proinflammatory mediator and "[t]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition patentably new to the discoverer." *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming, of an unknown property, which is inherently present in the prior art, does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ430, 433 (CCPA 1977) (MPEP § 2112).

Rezai discloses that the cell is a sympathetic neuron in a patient suffering from, or at risk for disease or disorder such as burns or spinal cord injury (see Rezai page 7, paragraphs 50-51). It is inherent that these diseases or disorders are mediated by an inflammatory cytokine cascade and the Examiner makes reference to Applicant's disclosure pages 8-12 (see Rezai page 1, paragraphs 9-10, page 2, paragraphs 10-11, page 3, paragraphs 26-30, page 5, paragraphs 44-45, page 6, paragraphs 46-48 and 50, page 7, paragraphs 50-56 and page 8, paragraphs 59-69). It is also inherent, or at least obvious to one having ordinary skill in the art at the time the invention was made

Art Unit: 3766

that a physician, nurse or equivalent would have "identified a mammalian subject suffering from, or at risk for, such diseases" before administering any stimulation of sympathetic neurons otherwise the physician, nurse or equivalent would be treating patients who do not even need treatment.

In regard to claims 2-4, 55, and 56, Rezai discloses that the electrode 122, used to stimulate the sympathetic neuron of interest, is coupled to a pulse generator, which may be implanted on or adjacent to the electrode 122 (see Rezai page 4, paragraph 37). The stimulation comprises an oscillating electrical signal, comprising a plurality of electrical pulses, operated at a frequency range between about 2 Hz and 2500 Hz, having a voltage between about 0.1 V to about 20 V and a pulse width between 10 microseconds to about 1,000 microseconds (see Rezai page 2, paragraph 19 and page 5, paragraph 38), wherein a plurality of electrical pulses are applied to the neuron (see Rezai page 1, paragraphs 2, 4-5 and 9).

In regard to claims 8-10, 57-65, and 130-138 Rezai discloses that the electrode 122 may be used to electrically stimulate any cervical ganglion or ganglia, thoracic ganglion or ganglia, lumbar ganglion or ganglia or sacral ganglia or any combination thereof associated with a particular physiological disorder to be affected, modulated, treated, alleviated or ameliorated (see Rezai page 1, paragraph 5). The Examiner takes the position that these "ganglion or ganglia" disclosed by Rezai comprise neurons of the splenic nerve and makes reference to Applicant's disclosure pages 17-18.

In regard to claims 57-62 and 140-199, Rezai discloses that the method is capable of effecting a variety of physiological disorders or pathological conditions by placing an

Art Unit: 3766

electrode 122 adjacent to or in communication with at least one ganglion along the sympathetic nerve chain and stimulating the at least one ganglion until the physiological disorder or pathological condition has been effected (see Rezai Abstract, page 1, paragraphs 4-5 and page 4, paragraph 36). Rezai discloses that postganglionic sympathetic nerve fibers converge, in small nodes of nerve cells, called ganglia (see Rezai page 3, paragraph 28) and further discloses that the method may comprise stimulation any cervical ganglia, thoracic ganglia, lumbar ganglia or sacral ganglia or combination thereof (see Rezai page 1, paragraph 5). Rezai also discloses that the cell is a sympathetic neuron in a patient suffering from, or at risk for disease or disorder such as burns or spinal cord injury (see Rezai page 7, paragraphs 50-51). It is inherent that an inflammatory cytokine cascade mediates these diseases or disorders and the Examiner makes reference to Applicant's disclosure pages 8-12 (see Rezai page 1, paragraphs 9-10, page 2, paragraphs 10-11, page 3, paragraphs 26-30, page 5, paragraphs 44-45, page 6, paragraphs 46-48 and 50, page 7, paragraphs 50-56 and page 8, paragraphs 59-69). It is also inherent, or at least obvious to one having ordinary skill in the art at the time the invention was made that a physician, nurse or equivalent would have "identified and/or diagnosed a mammalian subject suffering from or at risk for, such diseases" before administering any stimulation of sympathetic neurons otherwise the physician, nurse or equivalent would be • treating patients who do not even need treatment. Rezai also discloses that an electrode 122, coupled to a pulse generator is used to stimulate the sympathetic neuron of interest (see Rezai page 4, paragraph 37), wherein electrode 122 may be used to electrically stimulate any cervical

Art Unit: 3766

ganglion or ganglia, thoracic ganglion or ganglia, lumbar ganglion or ganglia or sacral ganglia or any combination thereof associated with a particular physiological disorder to be affected, modulated, treated, alleviated or ameliorated (see Rezai page 1, paragraph 5). Rezai discloses that the method is capable of effecting a variety of physiological disorders or pathological conditions by placing an electrode 122 adjacent to or in communication with at least one ganglion along the sympathetic nerve chain and stimulating the at least one ganglion until the physiological disorder or pathological condition has been effected (see Rezai Abstract, page 1, paragraphs 4-5 and page 4, paragraph 36). Rezai teaches that postganglionic sympathetic nerve fibers converge, in small nodes of nerve cells, called ganglia (see Rezai page 3, paragraph 28) and further discloses that the method may comprise stimulation any cervical ganglia, thoracic ganglia, lumbar ganglia or sacral ganglia or combination thereof (see Rezai page 1, paragraph 5).

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. **Claims 63-67 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rezai (US 2002/0116030).**

Rezai discloses the claimed invention as discussed above except that the method does not further comprise direct stimulation of a peripheral tissue or organ served by the splenic nerve. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method as taught by Rezai with direct stimulation of a peripheral tissue or organ served by the Splenic nerve, because Applicant has not disclosed that such stimulation provides an advantage, is used for a particular purpose, or solves a stated problem. One of ordinary skill in the art, furthermore, would have expected applicant's invention to perform equally well with the sympathetic nerve stimulation as taught by Rezai, because it stimulation in an amount effective to inhibit the release of a proinflammatory mediator and since it appears to be an arbitrary design consideration which fails to patentably distinguish over Rezai. Therefore, it would have been an obvious matter of design choice to modify Rezai to obtain the invention as specified in the claim(s).

7. Claims 18-42 and 66-70 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rezai (US 2002/0116030) in view of Tracey (U.S. 6,610,713).

In regard to claims 18-42 and 66-70, Rezai discloses the claimed invention as discussed above except that the inhibition of a proinflammatory mediator is not specified to be inhibition of an inflammatory cytokine called TNF- α . Tracey, however, teaches that inflammation and other deleterious conditions (such as ischemia) are often induced by proinflammatory cytokines such as tumor necrosis factor (TNF- α) (see Tracey columns 1-2). Since the method of Rezai is specified for use in treating ischemia in addition to burns and spinal cord injury (see Rezai pages 5-7), it would have been obvious to one

Art Unit: 3766

having ordinary skill in the

art at the time the invention was made to modify the method of King in view of Tracey to comprise inhibition of the inflammatory cytokine TNF- α in order to treat ischemia.

Further in regard to claims 18-42 and 66-70, Rezai discloses the claimed invention as discussed above except that the proinflammatory mediator is not specified to be a chemokine. Tracey, however, teaches a method of stimulating a nerve to inhibit the release of a pro-inflammatory cytokine such as IL-8. IL-8 is produced in acute and chronic inflammation to mobilize and activate white blood cells so it is inherent that inhibition of IL-8 inhibits the mobilization and activation of white blood cells during acute and chronic inflammation. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of Rezai in view of Tracey to comprise inhibition of the inflammatory chemokine such as IL-8 in order to stop the mobilization and/or activation of white blood cells during acute and chronic inflammatory responses (such as ischemia) in a patient.

8. Claims 1-4, 8-10, 15, and 54-67 are rejected under 35 U.S.C. 103(a) as being unpatentable over King (U.S. 6,058,331).

In regard to claims 1, 15, and 54, King discloses a method comprising stimulating a sympathetic neuron of a mammalian subject in an amount effective to inhibit the release of a proinflammatory mediator/inhibit the inflammatory cytokine cascade. King specifies that the method is used for improving blood flow, for helping to restore tissue health and for treating organ ischemia using spinal cord or peripheral nerve electrical stimulation with closed loop feedback control (see King Title and Abstract) comprising the steps of

Art Unit: 3766

identifying a mammalian subject suffering from organ ischemia using external sensor 30 or internal sensor 40 (see King column 5, lines 31-67 and column 6, lines 1-54) and stimulating a sympathetic neuron (either in the spinal cord or the peripheral nervous system) of the subject (see King, Abstract, Figs. 1-3, columns 1-2, column 3, lines 28-60, column 4, lines 29-67, column 5, lines 1-67, column 7, lines 41-56 and column 10, lines 8-59). It is inherent that organ ischemia is a disease or disorder that is mediated by an inflammatory cytokine cascade and the Examiner makes reference to Applicant's disclosure pages 8-12. The Examiner takes position that the plurality of electrical pulses delivered by lead 16 of King -- having amplitudes of 0.1 to 20 volts, pulse widths varying from 60 to 1000 microseconds and repetition rates varying from 5 to 185 Hz or more -- is synonymous with an "amount effective to inhibit the release of a proinflammatory mediator" due to Applicant's disclosure pages 17 and 26-28 (see King column 10, lines 8-24). King specifies that the method may be used to inhibit sympathetic activity/outflow (see King column 5, lines 28-31, column 7, lines 42-56 and column 10, lines 8-24). Since sympathetic nervous activity inherently is a major controller/contributor to the neurogenic contribution to inflammation in the body, a method that inhibits such sympathetic nervous activity (such as the method of King) inherently inhibits release of a proinflammatory cytokine cascade. The Examiner also notes that although the method of King is not explicitly disclosed "to inhibit the release of a proinflammatory mediator" or to "inhibit the inflammatory cytokine cascade", the electrical pulses delivered by lead 16 of the King method are capable of inhibiting the release of a proinflammatory mediator/the inflammatory cytokine cascade for the

reasons discussed above and "[t]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition patentably new to the discoverer:" *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of an unknown property, which is inherently present in the prior art, does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ430, 433 (CCPA 1977) (MPEP § 2112).

King discloses the claimed invention as discussed above except that it is not specified that the method be used to treat cerebral infarction. Since King does disclose at column 7, lines 42-56 that the method "may be utilized to improve blood flow in other parts of the body in addition to the limbs including, for example, human organs" and further that the method may be Used to "prevent tissue degeneration" and "maintain a constant tissue blood flow" it would have been obvious to one having ordinary skill in the art at the time the invention was made to use the method of King to treat cerebral infarction. It is well known in the art that cerebral infarction is caused by ischemia (i.e. disturbed perfusion or lack of blood flow to the brain which causes cells to die or be seriously damaged).

In regard to claims 2-5 and 55-62, King discloses that an implanted stimulation electrode delivers a plurality of electrical pulses to a sympathetic neuron via an implantable signal generator 14 (see King Figs. 1-3, column 3, lines 44-48, column 4, lines 29-67, column 5, lines 1-31 and column 10, lines 8-24).

In regard to claims 6-13, 23-24 and 29-31, in addition to the arguments presented

Art Unit: 3766

above, King discloses that lead 18 may have stimulation electrodes that may be positioned at spinal vertebral levels T8-L1. It is inherent that the splenic nerve is located at these vertebral levels. It is inherent that postganglionic sympathetic nerve fibers converge, in small nodes of nerve cells, called ganglia and King specifies that the stimulation lead 18 may also be position adjacent to the lumbar sympathetic ganglia (see King column 4, lines 66-67 and column 5, lines 1-31).

In regard to claims 63-67, King discloses the claimed invention as discussed above except that the method does not further comprise direct stimulation of a peripheral tissue or organ served by the splenic nerve. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method as taught by King with direct stimulation of a peripheral tissue or organ served by the splenic nerve, because Applicant has not disclosed that such stimulation provides an advantage, is used for a particular purpose, or solves a stated problem. One of ordinary skill in the art, furthermore, would have expected applicant's invention to perform equally well with the sympathetic nerve stimulation as taught by King, because the stimulation is in an amount effective to inhibit the release of a proinflammatory mediator and since it appears to be an arbitrary design consideration which fails to patentably distinguish over King. Therefore, it would have been an obvious matter of design choice to modify King to obtain the invention as specified in the claim(s). 26. Claims 14-18, 26 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over King in view of Tracey. In regard to claims 14-17, King discloses the claimed invention ,as discussed above except that the inhibition of a proinflammatory mediator is not specified

Art Unit: 3766

to be inhibition of an inflammatory cytokine called TNF-a. Tracey, however, teaches that inflammation and other deleterious conditions (such as ischemia) are often induced by proinflammatory cytokines such as tumor necrosis factor (TNF-a) (see Tracey columns 1-2). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of King in view of Tracey to comprise inhibition of the inflammatory cytokine TNF-a in order to treat ischemia.

27. In regard to claim 18, King discloses the claimed invention as discussed above except that the proinflammatory mediator is not specified to be a chemokine. Tracey, however, teaches a method of stimulating a nerve to inhibit the release of a proinflammatory cytokine such as IL-8. IL-8 is produced in acute and chronic inflammation to mobilize and activate white blood cells so it is inherent that inhibition of IL-8 inhibits the mobilization and activation of white blood cells during acute and chronic inflammation. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of King in view of Tracey to comprise inhibition of the inflammatory chemokine such as IL-8 in order to stop the mobilization and/or activation of white blood cells during acute and chronic inflammatory responses (such as ischemia) in a patient.

9. Claims 18-42 and 66-70 are rejected under 35 U.S.C. 103(a) as being unpatentable over King (US 6,610,713) in view of Tracey (US 6,058,331).

In regard to claims 18-42 and 66-70, King discloses the claimed invention, as discussed above except that the inhibition of a proinflammatory mediator is not specified to be inhibition of an inflammatory cytokine called TNF-a. Tracey, however, teaches that

inflammation and other deleterious conditions (such as ischemia) are often induced by proinflammatory cytokines such as tumor necrosis factor (TNF-a) (see Tracey columns 1-2). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of King in view of Tracey to comprise inhibition of the inflammatory cytokine TNF-a in order to treat ischemia.

Further in regard to claims 18-42 and 66-70, King discloses the claimed invention as discussed above except that the proinflammatory mediator is not specified to be a chemokine. Tracey, however, teaches a method of stimulating a nerve to inhibit the release of a pro-inflammatory cytokine such as IL-8. IL-8 is produced in acute and chronic inflammation to mobilize and activate white blood cells so it is inherent that inhibition of IL-8 inhibits the mobilization and activation of white blood cells during acute and chronic inflammation. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the method of King in view of Tracey to comprise inhibition of the inflammatory chemokine such as IL-8 in order to stop the mobilization and/or activation of white blood cells during acute and chronic inflammatory responses (such as ischemia) in a patient.

10. Claims 1-4, 18-42, 17, 54-62, 66-70, and 140-199 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tracey (US 6,610,713) in view of Sherwood "Human Physiology: From Cells to Systems".

In regard to claims 1-4, 17-21, 54-62, and 140-199, Tracey discloses a method for inhibiting the release of a pro-inflammatory cytokine from a mammalian cell/for inhibiting the inflammatory cytokine cascade comprising stimulating a neuron of a

Art Unit: 3766

mammalian subject in an amount effective to inhibit the release of the pro-inflammatory cytokine (see Tracey column 10, lines 17-56). Tracy specifies that the cell is in a patient suffering from, or at risk for, a condition mediated by an inflammatory cytokine cascade such as endotoxic shock, allergy, anaphylactic shock, sepsis, septicemia, cachexia, septic abortion, disseminated bacteremia, burns, Rheumatoid arthritis, spinal cord injury, allograft rejection, graft-versus-host disease, multiple sclerosis, Alzheimer's disease, etc. (see Tracy columns 1-2 and columns 21-22). Applicant differs from Tracey in that the stimulation comprises electrical stimulation of the sympathetic nervous system (versus electrical stimulation of the parasympathetic nervous system as taught by Tracey). The Examiner takes the position that it is conventional and well known in the art or neural stimulation that stimulation of either branch of the autonomic nervous system (i.e. either the parasympathetic branch or the sympathetic branch) may have the same effects on the body of a patient depending on the parameters of stimulation selected (i.e. low frequency for stimulation or high frequency for inhibition). One having ordinary skill in the art would know that if parasympathetic system is manipulated with electrical pulses to achieve a desired effect, then essentially the same effect could also be achieved with electrical pulses to the sympathetic system (except in a reciprocal fashion) and either choice is an obvious variant over the other. As supporting documentation the Examiner is submitting a few pages from a standard textbook of Human Physiology. On page 227 the paragraph beginning with there is an analogy of controlling heart rate with a person driving a car. Think of this like a person driving a car with one foot on the brake and the other foot on the accelerator. Either depressing the

Art Unit: 3766

brake (parasympathetic) or relaxing the accelerator (sympathetic) will slow the car. The same rationale would apply to manipulating the inflammatory response of the body with either the parasympathetic or sympathetic division(s) using electrical stimulation.

30.

In regard to claims 18-42 and 66-70, see Tracey column 1, lines 28-34 and column 3, lines 6-18.

In regard to claim 18, the Examiner takes the position that since the previously modified Tracey reference discloses a method for inhibiting the release of a pro-inflammatory cytokine such as IL-8, then the method also inherently inhibits the release of a pro-inflammatory chemokine (see column 6, lines ~55-61). A chemokine is synonymous with various cytokines produced in acute and chronic inflammation that mobilize and activate white blood cells such as IL-8.

11. Claims 2-4 and 55-62 are rejected under 35 U.S.C. 103(a) as being unpatentable over Tracy (US 6,610,713) in view of Sherwood as applied to claims 1-2 and 27 above, and further in view of Whitehurst et al. (U.S. 6,735,475 -- herein Whitehurst.)

The previously modified Tracy reference discloses the claimed invention as discussed above except it is not specified that electrical pulses be provided to a sympathetic neuron/ganglia/postganglionic neuron via an implanted pulse generator. The Examiner takes the position that electrically modulating the sympathetic nervous system with electrical pulses using an implanted pulse generator is conventional and well known in the art with Whitehurst being but one example. Whitehurst discloses a

small implantable stimulator, read as an implantable pulse generator 150 for applying electrical pulses to sympathetic ganglia or postganglionic neurons in order to interrupt or alter the inflammatory cytokine cascade in a patient (see Whitehurst Abstract, column 8, lines 10-56, column 10, lines 30-43, column 14, lines 43-56 and columns 16-19).

Double Patenting

12. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619. (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

13. A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to

Art Unit: 3766

be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

14. Claims 1-4, 8-10, 15, 17-42, 54-67, and 130-199 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-69 of copending Application No. 10/820,937. Although the conflicting claims are not identical, they are not patentably distinct from each other because the current claims are a broadening of the scope of the claims presented in Application No. 10/820,937 or an obvious variant thereof.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Response to Arguments

15. Applicant's arguments, see Remarks, filed 22 May 2007, with respect to the rejection(s) of claim(s) 1-4, 8-10, 14, 17-42, 57-70, and 130-197 under Kees et al. have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection (see above) has been made.

Conclusion

Art Unit: 3766

16. In view of the new grounds of rejection made above, this action is **NON-FINAL**.

17. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Brian T. Gedeon whose telephone number is (571) 272-3447. The examiner can normally be reached on M-F 8:30-5:00.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela D. Sykes can be reached on (571) 272-4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Brian T. Gedeon
Patent Examiner
Art Unit 3766

BTG

Angela D. Sykes
Supervisory Patent Examiner
Art Unit 3766


CARL LAYNO
PRIMARY EXAMINER

Application/Control Number: 10/820,677
Art Unit: 3766

Page 19